Pharmacyte Biotech Inc (OTCMKTS:PMCB) has been running up the charts on its cannabis exposure, but saw a massive acceleration higher on Thursday for other powerful reasons, boosting the stock to four-month highs on nearly 20m shares in transactions on the open market. The catalyst was a pair of announcements that add up to a serious speculative opportunity.
First, the company announced that oncologist, Dr. Manuel Hidalgo, who is the Chief of the Division of Hematology-Oncology at Harvard Medical School’s Beth Israel Deaconess Medical Center, has accepted the role of Principal Investigator for PharmaCyte’s planned clinical trial. That was quickly chased by news that it has requested a pre-IND meeting with the FDA for its upcoming pancreatic cancer clinical trial.
Pharmacyte Biotech Inc (OTCMKTS:PMCB) frames itself as a clinical stage biotechnology company that focuses on developing and commercializing treatments for cancer and diabetes based upon a proprietary cellulose-based live cell encapsulation technology, known as Cell-in-a-Box. Its Cell-in-a-Box technology would be used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, and diabetes.
The company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer.
It is also developing a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes; and examining the benefits of the Cell-in-a-Box technology to develop therapies for cancer based upon the constituents of the Cannabis plant.
The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was founded in 1996 and is based in Silver Spring, Maryland.
Find out when PMCB stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
According to the company’s press materials, Dr. Hidalgo will once again be teamed up with renowned pancreatic cancer expert Dr. Daniel Von Hoff in PharmaCyte’s clinical trial.
Dr. Von Hoff is the Chief Development Officer at Translational Drug Development (TD2), the nation’s premiere oncology CRO and the company responsible for organizing and conducting PharmaCyte’s clinical trial. Dr. Von Hoff and Dr. Hidalgo worked together on the clinical trials that brought the industry what is now the gold standard and the FDA approved treatment for advanced pancreatic cancer, Abraxane plus gemcitabine.
PharmaCyte has already named a handful of clinical trial sites that are being considered which include the Mayo Clinic in Scottsdale, Arizona, the Beth Israel Deaconess Cancer Center in Boston, the Dana-Farber Cancer Institute in Boston, the Baylor Cancer Center in Dallas, the City of Hope Cancer Center in Los Angeles and sites in Germany and Spain.
The market is reacting to the gravity of these announcements, which paint a clear picture of credibility in terms of the pre-trial arrangements. That puts investors in a position of needing to constantly evaluate what may end up being a monster market opportunity for a company that has been powerfully beaten down over recent years. The result may be a sense of a dramatic discount risk opportunity at hand.
Indeed, the chart shows 82% tacked on to share pricing for the listing in the past week, a rally that has pushed up against longer standing distributive pressure in the stock. That said, PMCB stock has a track record that includes a number of dramatic bounces. In addition, the company has seen an influx in interest of late, with the stock’s recent average trading volume running greater than 180% beyond what we have been seeing over the larger time frame.
Currently trading at a market capitalization of $46.8M, PMCB has a decent store ($2.34M) of cash on the books, in a pool of total assets a bit over $7.5M, which stands against virtually no total accumulated debt.
With an unequivocal establishment of a platform of credibility, the world will be watching the results here and pricing in a “Heisenberg” probabilistic sense of the value of the end result of full success multiplied by the coefficient risk of no success in the trials. This may be an extremely interesting stock moving forward and we will be following it closely. For continuing coverage on shares of PMCB stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!